Multi-center, Open, Randomized, Parallel Group Comparison of Cycle Control for Seven Cycles and Endometrial Safety in a Subgroup for Thirteen Cycles of Contraceptive Patch SH P00331F (0.9 mg Ethinylestradiol/1.9 mg Gestodene) vs. a Contraceptive Comparator Patch (0.6 mg Ethinylestradiol/6 mg Norelgestromin) in 400 Healthy Female Volunteers
Latest Information Update: 03 Aug 2021
At a glance
- Drugs Ethinylestradiol/gestodene (Primary) ; SHP 00331F (Primary) ; Ethinylestradiol/norelgestromin
- Indications Pregnancy
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Bayer; Bayer HealthCare Pharmaceuticals
- 02 Feb 2007 Status change from in progress to completed
- 17 Nov 2005 New trial record.